Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BioVectra Wins Kane Enzyme Contract

March 10, 2008 | A version of this story appeared in Volume 86, Issue 10

BioVectra, a Prince Edward Island-based contract manufacturer, has won a contract to make Kane Biotech's DispersinB, currently in preclinical development for the treatment of chronic wounds. The product is an enzyme that can both inhibit and disperse bacterial biofilms, a grouping of microorganisms that stick to a surface, such as a medical device, and protect themselves by making a liquid matrix. Conventional antibiotics have trouble penetrating biofilms. Kane, based in Winnipeg, Manitoba, says DispersinB has proven active against biofilms formed by bacteria including Staphylococcus epidermis, S. aureus, and Escherichia coli.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.